Scilex Appoints Kasowitz LLP as Legal Counsel

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jan 02 2026

0mins

Should l Buy SCLX?

Scilex Holding Company has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the Company continues to advance and protect its proprietary pharmaceutical assets and development pipeline.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SCLX?" and start using high-conviction signals backed by rigorous historical data.

SCLX

$8.49+Infinity%1D

Analyst Views on SCLX

About SCLX

Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Scilex Makes $20 Million Strategic Investment in Quantum Scan

Jan 30 2026Newsfilter

Strategic Investment: Scilex Holding Company announced a $20 million strategic investment in Quantum Scan Holdings, Inc., aimed at supporting the development of innovative medical technologies in preventive diagnosis and prognosis, which is expected to enhance the company's competitiveness in this trillion-dollar market.
Support for Technological Innovation: This investment will enable Quantum Scan to develop advanced diagnostic platforms and scalable healthcare solutions, improving accessibility and efficiency in healthcare delivery, thereby addressing the growing market demand and enhancing patient care experiences.
Synergistic Effects: Scilex believes this investment complements its substantial investment in Datavault AI, further solidifying its strategic positioning in the non-opioid pain management sector and driving overall business growth.
Leadership Confidence: Quantum Scan CEO Mustaq Patel stated that Scilex's investment will accelerate their innovation in medical technologies, reflecting confidence in their team and vision, indicating potential for long-term value creation within the healthcare ecosystem.